News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Investor Alerts Year All Years 2022 2021 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard 06.21.2022 Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers Read More > 06.02.2022 Nuvalent to Present at the 2022 Jefferies Healthcare Conference Read More > 05.12.2022 Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results Read More > 04.08.2022 Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 Read More > 04.07.2022 Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference Read More > 03.31.2022 Nuvalent Appoints Anna Protopapas as Chair of Board of Directors Read More > 03.29.2022 Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results Read More > 03.08.2022 Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 Read More > 03.02.2022 Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference Read More > 02.03.2022 Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors Read More > 01.07.2022 Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor Read More > 01.04.2022 Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference Read More > 11.10.2021 Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results Read More > 10.07.2021 New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC Read More > 09.08.2021 Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results Read More > 08.02.2021 Nuvalent Announces Closing of Upsized Initial Public Offering Read More > 07.28.2021 Nuvalent Announces Pricing of Initial Public Offering Read More > 05.11.2021 Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers Read More > 04.10.2021 Nuvalent Presents Preclinical Data Demonstrating That ROS1 Inhibitor NUV-520 and ALK Inhibitor NUV-655 are Selective, Brain-Penetrant, and Active Against Drug-Resistance Mutations Read More > 03.23.2021 Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer Read More > 01.27.2021 Nuvalent Launches with $50M Series A Financing from Deerfield Management to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers Read More > Show 5102550100 per page
